Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
JNJ
Johnson & Johnson
$188.64
Login to see Johnson & Johnson (JNJ) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Upgraded on attractively valued
Pays a reliable dividend
Outperform the market
Chart
$176.96 (+6.60%)
$156.81 (+20.30%)
$146.55 (+28.72%)
$165.12 (+14.24%)
JNJ has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Investors losing confidence
JNJ overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Earnings increase YoY
Reported a strong earnings
Revenue increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Pays a reliable dividend
Future
Future
Earnings are forecast to grow
Outperform the market
Trading below its fair value
JNJ Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
JNJ Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayJNJ Earnings
The TTM reflects 12-month period, providing review of JNJ financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
SNDX
15.60
+1.04%
REGN
600.00
0.00%
PFE
27.37
+1.07%
PCRX
24.84
+1.06%
NBTX
20.51
+3.17%
What is JNJ current stock price?
What are JNJ stock strengths?
What risks are associated with JNJ stock?
When is JNJ next earnings report?
What is JNJ market cap and volume?
What is JNJ's current Stock IQ?
Should I buy JNJ stock right now?
Is JNJ a Strong Buy right now?
What does a 'Strong Buy' rating mean for JNJ?
What does a 'Strong Sell' rating mean for JNJ?
What factors influence JNJ's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
JNJ
Johnson & Johnson
Current Price
$188.64
Stock Insights
Strengths
Earnings are forecast to grow
Upgraded on attractively valued
Pays a reliable dividend
Outperform the market
Linked to JNJ
SNDX
15.60
+1.04%
REGN
600.00
0.00%
PFE
27.37
+1.07%
PCRX
24.84
+1.06%
NBTX
20.51
+3.17%
Login to unlock Johnson & Johnson (JNJ) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$176.96 (+6.60%)
$156.81 (+20.30%)
$146.55 (+28.72%)
$165.12 (+14.24%)
JNJ Analysts Opinion
JNJ Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Earnings increase YoY
Reported a strong earnings
Revenue increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Pays a reliable dividend
Future
Future
Earnings are forecast to grow
Outperform the market
Trading below its fair value
JNJ Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
JNJ Street view is extremely bullish and have positive views on the near-term outlook
JNJ has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Investors losing confidence
Average key support and resistance price levels.
Login to displayJNJ Earnings
The TTM data reflects the most recent 12-month period, providing overview of JNJ financial performance.
JNJ Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
JNJ Latest Analysis
Wells Fargo Upgrades Johnson & Johnson (JNJ). Fintel reports that on October 3 2025 Wells Fargo upgraded their outlook for Johnson &. Johnson (NYSE:JNJ) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 1.14% Downside
Today
Johnson & Johnsons Options Frenzy: What You Need to Know. Investors with a lot of money to spend have taken a bearish stance on ).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals we don'.t know. But when something this big happens with JNJ it often means somebody knows something is about to happen.So how do we know what these investors
Today
This Johnson & Johnson Analyst Turns ish. Here Are Top 5 Upgrades For Friday. Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes including upgrades downgrades and initiations please see our analyst ratings page.Morgan Stanley analyst Ronald Kamdem upgraded CURB) from Equal-Weight to Overweight and maintained the price target of $27. Curbline Properties shares closed at $22.82 on Thursday. See how other analysts view this stock.Sco
Today
J&J upgraded at Wells Fargo on valuation pharma potential.
Today
Johnson & Johnson is a buy as drug sales continue to improve Wells Fargo says. The bank upgraded the pharma giant to overweight from equal weight.
Today
Barclays Maintains a Hold Rating on Johnson & Johnson (JNJ) With a $176 PT. Johnson &. Johnson (NYSE:JNJ) is one of the best medical stocks to buy now. In a report released on September 30 Matt Miksic from Barclays maintained a Hold rating on Johnson &. Johnson (NYSE:JNJ) and set a price target of $176.00. The rating update came after Johnson &. Johnson (NYSE:JNJ) reported on September 29 the [….]
Today
Johnson & Johnson (JNJ) Gains FDA Nod for TREMFYA Subcutaneous Therapy. Johnson &. Johnson (NYSE:JNJ) ranks among the top picks for a retirement portfolio. On September 26 Johnson &. Johnson (NYSE:JNJ) reported that the US FDA had approved a subcutaneous induction protocol of TREMFYA (guselkumab) for the treatment of individuals with moderate to severe active ulcerative colitis. With this approval TREMFYA becomes the first IL-23 inhibitor [….]
Thu Oct 2, 2025
Noteworthy Tuesday Option Activity: IDT JNJ APP. Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in IDT Corp (Symbol: IDT) where a total volume of 1055 contracts has been traded thus far today a contract volume which is representative of approximately 10550
Tue Sep 30, 2025
Jim Cramer on Johnson & Johnson: Its Differentiating Itself From the Pack. Johnson &. Johnson (NYSE:JNJ) is one of the stocks Jim Cramer shared his take on. Cramer appreciated the companys research and products during the episode as he commented: Even though its been a terrible year for healthcare stocks there are still a handful of real winners like Johnson and Johnson up more than 24% year [….]
Tue Sep 30, 2025
Johnson & Johnson (JNJ) to Withdraw Acid Reflux Treatment in Some Markets. Johnson &. Johnson (NYSE:JNJ) is one of the best conservative stocks to buy now. On September 23 the company announced plans to withdraw the LINX Reflux Management System in certain countries. The company has cited commercial reasons for withdrawing the device used to treat acid reflux disease. The withdrawal follows a thorough evaluation of market [….]
Tue Sep 30, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings